A model of the natural history of screen-detected prostate cancer [2]

British Journal of Cancer

Volumn 95, Issue 8, 2006, Pages 1122-1123

  Metcalfe, C ^a   Lane, J A ^a   Hamdy, F ^b   Neal, D ^c   Donovan, J L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; DISEASE COURSE; LETTER; MODEL; PRIORITY JOURNAL; PROSTATE CANCER;

HUMANS; MALE; MASS SCREENING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 33750221742     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603368     Document Type: Letter

References (11)

1. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101
2. Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975-980
3. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson S-O, Bratell S, Spângberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami H-O, Norlén BJ, Johansson J-E (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984
4. Chodak GW, Thisted RA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J (1994) Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248
5. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D, Mills N, Smith M, Noble S, Lane A (2003) Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess 7(14): 1-88
6. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schröder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878
7. Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ (in press) Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer (Doi: 10.1002/ijc.22158)
8. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D (2005) Early outcomes of active surveillance for localized prostate cancer. BJU Int 95: 956-960
9. Parker C (2004) Active surveillance of early prostate cancer: rationale, initial results and future developments. Prostate Cancer Prostatic Dis 7: 184-187
10. Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94: 1361-1368
11. Press Association (2006) Study warns of prostate cancer therapy risks. Guardian Unlimited (http://www.guardian.co.uk, accessed 25th May 2006)